Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency

Title	Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency
Authors	Zafeiris Zafeiriou, Diletta Bianchini, Robert Chandler, Pasquale Rescigno, Wei Yuan, Suzanne Carreira, Maialen Barrero, Antonella Petremolo, Susana Miranda, Ruth Riisnaes, Daniel Nava Rodrigues, Bora Gurel, Semini Sumanasuriya, Alec Paschalis, Adam Sharp, Joaquin Mateo, Nina Tunariu, Arul M. Chinnaiyan, Colin C. Pritchard, Kevin Kelly, Johann S. de Bono
Magazine	European Urology
Date	01/01/2019
DOI	10.1016/j.eururo.2018.09.048
Introduction	Platinum-based treatments have not been confirmed to improve survival rates in advanced prostate cancer. However, clear evidence exists that some prostate cancers have homologous recombination DNA repair defects, which are synthetically lethal when combined with poly(ADP)-ribose polymerase inhibitors and platinum. This has led to increased interest in using these treatments for certain diseases. We present three cases of advanced castration-resistant prostate cancer with HRD defects showing significant responses to carboplatin.
Quote	Zafeiris Zafeiriou, Diletta Bianchini and Robert M. Chandler et al. Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. Eur. Urol. 2019. DOI: 10.1016/j.eururo.2018.09.048
Element	Platinum (Pt)
Industry	Medical Devices , Pharmaceutical Industry , Research & Laboratory